TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38394119

Group type: EXPERIMENTAL
Intervention: Healer-led PPE training
Number of subjects: 136

Group type: COMPARATOR
Intervention: HCW-led PPE training
Number of subjects: 136
Study: 38394185

Group type: EXPERIMENTAL
Intervention: Online life skills programme
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control group (no intervention during the study)
Number of subjects: 207
Study: 38394279

Group type: EXPERIMENTAL
Intervention: BETTER transitional care intervention for 16 weeks post-hospital discharge
Number of subjects: 436

Group type: COMPARATOR
Intervention: Usual transitional care management
Number of subjects: 436
Study: 38394298

Group type: EXPERIMENTAL
Intervention: Schistoscope
Number of subjects: 1137

Group type: COMPARATOR
Intervention: Conventional microscopy
Number of subjects: 1137
Study: 38394353

Group type: EXPERIMENTAL
Intervention: CAD/CAM fixed retainers
Number of subjects: 181

Group type: COMPARATOR
Intervention: Conventional multistranded fixed retainers
Number of subjects: 181
Study: 38394384

Group type: EXPERIMENTAL
Intervention: Darolutamide
Number of subjects: 1509

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1509
Study: 38394387

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOAC) treatment with measurement of DOAC levels
Number of subjects: 1657
Study: 38394657

Group type: EXPERIMENTAL
Intervention: Leukocyte- and platelet-rich fibrin (L-PRF)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Commercially available fibrin sealants (control)
Number of subjects: 350
Study: 38394666

Group type: EXPERIMENTAL
Intervention: Daratumumab-carfilzomib-lenalidomide-dexamethasone (D-KRd) induction, autologous stem cell transplantation (ASCT), D-KRd consolidation, second ASCT, and daratumumab-lenalidomide maintenance.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: D-KRd induction/consolidation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: D-KRd with tandem transplant
Number of subjects: 50
Study: 38394720

Group type: COMPARATOR
Intervention: DCD only (noASD)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: DCD and suspected ASD (sASD)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: DCD and confirmed ASD (cASD)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Total group (DCD with and without ASD)
Number of subjects: 102
Study: 38395023

Group type: EXPERIMENTAL
Intervention: Enabler mode
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Relayer mode
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Delayer mode
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Decliner mode
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Persuader mode
Number of subjects: 68
Study: 38395537

Group type: EXPERIMENTAL
Intervention: CAD-assisted colonoscopy
Number of subjects: 916

Group type: COMPARATOR
Intervention: Conventional colonoscopy
Number of subjects: 916

Group type: EXPERIMENTAL
Intervention: CAD first in tandem colonoscopy
Number of subjects: 916

Group type: COMPARATOR
Intervention: Conventional colonoscopy first in tandem colonoscopy
Number of subjects: 916
Study: 38395539

Group type: COMPARATOR
Intervention: Automated text messaging and monitoring (AMMI) only
Number of subjects: 1037

Group type: EXPERIMENTAL
Intervention: AMMI plus peer support
Number of subjects: 1037

Group type: EXPERIMENTAL
Intervention: AMMI plus strengths-based telehealth coaching
Number of subjects: 1037

Group type: EXPERIMENTAL
Intervention: AMMI plus peer support and coaching
Number of subjects: 1037

Group type: COMPARATOR
Intervention: Control group (AMMI only)
Number of subjects: 1037
Study: 38395743

Group type: EXPERIMENTAL
Intervention: Lifestyle-integrated Functional Exercise Program (LiFE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group-delivered Lifestyle-integrated Functional Exercise Program (gLiFE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LiFE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: gLiFE
Number of subjects: 0
Study: 38395824

Group type: EXPERIMENTAL
Intervention: SRP with intra-pocket application of diode laser (980 nm)
Number of subjects: 50

Group type: COMPARATOR
Intervention: SRP with systemic antibiotic administration (spiramycin and metronidazole)
Number of subjects: 50
Study: 38395833

Group type: EXPERIMENTAL
Intervention: 4-EI (four-item exerciser identity measure)
Number of subjects: 1709

Group type: EXPERIMENTAL
Intervention: 4-HEI (four-item healthy-eater identity measure)
Number of subjects: 1709

Group type: EXPERIMENTAL
Intervention: 4-EI and 4-HEI in Successful weight loss category
Number of subjects: 1709

Group type: EXPERIMENTAL
Intervention: 4-EI and 4-HEI in Regain weight loss category
Number of subjects: 1709

Group type: EXPERIMENTAL
Intervention: 4-EI and 4-HEI in Unsuccessful weight loss category
Number of subjects: 1709

Group type: EXPERIMENTAL
Intervention: 4-EI and 4-HEI in maintaining ≥ 5% weight loss for > 1 year
Number of subjects: 1709

Group type: EXPERIMENTAL
Intervention: 4-EI and 4-HEI in not maintaining ≥ 5% weight loss for > 1 year
Number of subjects: 1709
Study: 38395903

Group type: EXPERIMENTAL
Intervention: ONLOOP intervention (personalized reminders and toolkit)
Number of subjects: 862

Group type: COMPARATOR
Intervention: Delayed intervention (control group)
Number of subjects: 862
Study: 38395910

Group type: EXPERIMENTAL
Intervention: Interprofessional collaboration intervention for primary care physicians and nurses
Number of subjects: 0
Study: 38395948

Group type: EXPERIMENTAL
Intervention: autologous natural dendritic cell (nDC)
Number of subjects: 148

Group type: COMPARATOR
Intervention: placebo (PL)
Number of subjects: 148
Study: 38395969

Group type: EXPERIMENTAL
Intervention: nDC treatment
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 148
Study: 38395980

Group type: EXPERIMENTAL
Intervention: tACS (transcranial electrical stimulation)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Cognitive training with tACS
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 62
Study: 38396126

Group type: EXPERIMENTAL
Intervention: Supplementation with 90 mg vitamin C, 30 mg α-tocopherol (vitamin E), 18 mg vitamin B
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard prenatal vitamin (control group)
Number of subjects: 0
Study: 38396134

Group type: EXPERIMENTAL
Intervention: Implantable ultrasound device with carboplatin
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Carboplatin administration before sonication
Number of subjects: 33
Study: 38396172

Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields (TTFields) combined with CUSP9v3
Number of subjects: 0

Group type: COMPARATOR
Intervention: CUSP9v3
Number of subjects: 0
Study: 38396203

Group type: EXPERIMENTAL
Intervention: MENQOL intervention
Number of subjects: 1022
Study: 38396300

Group type: EXPERIMENTAL
Intervention: Combined vincristine, doxorubicin, cyclophosphamide, and etoposide (regimen I) plus radiation therapy (RT) for stage II/III disease.
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Regimen UH-1 (carboplatin added for stage IV disease, RT omitted for stage I if lymph nodes were sampled).
Number of subjects: 132

Group type: COMPARATOR
Intervention: AREN03B2 stage-appropriate chemotherapy.
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Combined studies for stage I (n=10), II (n=47), III (n=65), and IV (n=10) disease.
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Treatment without RT for stage I disease.
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Carboplatin-containing regimen for stage IV disease.
Number of subjects: 132
Study: 38396455

Group type: EXPERIMENTAL
Intervention: HER2 positivity
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ki-67 ≥ 20%
Number of subjects: 200
Study: 38398474

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation and oral antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no mechanical bowel preparation and oral antibiotics)
Number of subjects: 0
Study: 38398703

Group type: EXPERIMENTAL
Intervention: Chronic, latent toxoplasmosis treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38400102

Group type: EXPERIMENTAL
Intervention: Monovalent Omicron XBB.1.5-adapted BNT162b2 (single 30-μg dose)
Number of subjects: 0
Study: 38400158

Group type: EXPERIMENTAL
Intervention: SCTV01E-2
Number of subjects: 429

Group type: COMPARATOR
Intervention: SCTV01E
Number of subjects: 429
Study: 38400193

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV and MVA-BN-Filo vaccines
Number of subjects: 614
Study: 38400200

Group type: EXPERIMENTAL
Intervention: sIPV primary vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: sIPV booster vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: sIPV priming and booster vaccination
Number of subjects: 0
Study: 38400528

Group type: EXPERIMENTAL
Intervention: Patient-reported QoL
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Proxy-reported QoL
Number of subjects: 146
Study: 38400570

Group type: EXPERIMENTAL
Intervention: Etoposide, cytarabine, and pegfilgrastim (EAP) regimen
Number of subjects: 0
Study: 38400780

Group type: EXPERIMENTAL
Intervention: ONC201 administered D1D2 (twice-weekly)
Number of subjects: 12

Group type: COMPARATOR
Intervention: ONC201 administered once-weekly (D1)
Number of subjects: 12
Study: 38400813

Group type: EXPERIMENTAL
Intervention: Staccato alprazolam 1 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Staccato alprazolam 2 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Staccato placebo
Number of subjects: 36
Study: 38400905

Group type: EXPERIMENTAL
Intervention: Proactive financial navigation (FN) intervention
Number of subjects: 31

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 31
Study: 38400914

Group type: EXPERIMENTAL
Intervention: zilucoplan 0.3 mg/kg
Number of subjects: 174

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 174
Study: 38400919

Group type: EXPERIMENTAL
Intervention: Caffeine gum (300 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 38400942

Group type: EXPERIMENTAL
Intervention: CORE®
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Everion®
Number of subjects: 20
Study: 38400984

Group type: EXPERIMENTAL
Intervention: Integrated Care Approach for Breast Cancer Patients
Number of subjects: 0
Study: 38401036

Group type: EXPERIMENTAL
Intervention: L-Glutamine (0.1 g/kg twice daily, 0.3 g/kg twice daily, 0.6 g/kg once daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: L-Glutamine (multiple doses over 3 weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: L-Glutamine (oral therapy)
Number of subjects: 12
Study: 38401078

Group type: EXPERIMENTAL
Intervention: Spirulina (1.6g/day for 2 months)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 38401202

Group type: EXPERIMENTAL
Intervention: Satralizumab
Number of subjects: 131
Study: 38401551

Group type: EXPERIMENTAL
Intervention: Pyriproxyfen-pyrethroid LLINs
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Chlorfenapyr-pyrethroid LLINs
Number of subjects: 600

Group type: COMPARATOR
Intervention: Pyrethroid-only LLINs (reference group)
Number of subjects: 600
Study: 38401646

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 2602
Study: 38401647

Group type: EXPERIMENTAL
Intervention: NOAC monotherapy
Number of subjects: 960

Group type: COMPARATOR
Intervention: NOAC plus clopidogrel combination therapy
Number of subjects: 960
Study: 38401649

Group type: EXPERIMENTAL
Intervention: Early UFH administration (iv. bolus of 100 units/kg UFH)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Late UFH administration (iv. bolus of 100 units/kg UFH)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo (given after obtaining femoral vein access and at least 5 minutes prior to the start of the TSP)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo (given immediately after TSP)
Number of subjects: 410
Study: 38401691

Group type: EXPERIMENTAL
Intervention: Energy-restricted diets with different nutrient compositions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38401741

Group type: EXPERIMENTAL
Intervention: FODMAP powders (fructans, fructose, galacto-oligosaccharides, lactose, mannitol, sorbitol)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control (glucose)
Number of subjects: 117
Study: 38401785

Group type: EXPERIMENTAL
Intervention: care gap
Number of subjects: 13346

Group type: EXPERIMENTAL
Intervention: alert
Number of subjects: 13346

Group type: EXPERIMENTAL
Intervention: both (care gap and alert)
Number of subjects: 13346

Group type: COMPARATOR
Intervention: standard practice (control arm)
Number of subjects: 13346
Study: 38401789

Group type: COMPARATOR
Intervention: Multiple family group-based family strengthening intervention
Number of subjects: 89

Group type: COMPARATOR
Intervention: Group cognitive behavioral therapy intervention
Number of subjects: 89
Study: 38401796

Group type: EXPERIMENTAL
Intervention: FSIQ-RMS Symptoms domain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FSIQ-RMS Physical Impacts domain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FSIQ-RMS Cognitive/Emotional Impacts domain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FSIQ-RMS Coping Impacts domain
Number of subjects: 0
Study: 38401897

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation programme (CardioActive; CA) plus usual care
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 100
Study: 38401894

Group type: EXPERIMENTAL
Intervention: MS CATCH for 12 months
Number of subjects: 125

Group type: COMPARATOR
Intervention: Usual care for 6 months, then MS CATCH for 6 months
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: MS CATCH
Number of subjects: 125
Study: 38401903

Group type: EXPERIMENTAL
Intervention: Post-Intensive Care Syndrome interventions (specifics not provided)
Number of subjects: 0
Study: 38402053

Group type: EXPERIMENTAL
Intervention: Start to move protocol
Number of subjects: 69

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 69
Study: 38402046

Group type: EXPERIMENTAL
Intervention: LDR brachytherapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard of care (no brachytherapy)
Number of subjects: 35
Study: 38402096

Group type: EXPERIMENTAL
Intervention: PRONEtect Education Hub (digital platform)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Traditional lecture (control group)
Number of subjects: 80
Study: 38402173

Group type: EXPERIMENTAL
Intervention: Deferred cytoreductive nephrectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No surgery (control)
Number of subjects: 0
Study: 38402303

Group type: EXPERIMENTAL
Intervention: FluMos-v1 (mosaic influenza nanoparticle vaccine)
Number of subjects: 0
Study: 38402332

Group type: EXPERIMENTAL
Intervention: Orforglipron (LY3502970) 3 mg (study A)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Orforglipron (LY3502970) 16 mg (study B)
Number of subjects: 46
Study: 38402353

Group type: EXPERIMENTAL
Intervention: Salt substitute (75% sodium chloride and 25% potassium chloride by mass)
Number of subjects: 20995

Group type: COMPARATOR
Intervention: Regular salt (100% sodium chloride)
Number of subjects: 20995
Study: 38402361

Group type: EXPERIMENTAL
Intervention: Extensive ICU treatment (invasive ventilation for > 24 hours, continuous renal replacement therapy, or both)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing severity of acute illness
Number of subjects: 0
Study: 38402373

Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 155
Study: 38402374

Group type: EXPERIMENTAL
Intervention: Talquetamab QW (0.4 mg/kg weekly)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Talquetamab Q2W (0.8 mg/kg every other week)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Real-world physician's choice (RWPC)
Number of subjects: 288
Study: 38402467

Group type: EXPERIMENTAL
Intervention: Isatuximab plus carfilzomib-dexamethasone (Isa-Kd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carfilzomib-dexamethasone (Kd)
Number of subjects: 0
Study: 38402708

Group type: EXPERIMENTAL
Intervention: Intermittent low glycemic index therapy (LGIT)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Daily low glycemic index therapy (LGIT)
Number of subjects: 132
Study: 38402886

Group type: EXPERIMENTAL
Intervention: Sunitinib (37.5 mg per day)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 78
Study: 38403166

Group type: EXPERIMENTAL
Intervention: Timed voids (morning, afternoon, evening, overnight)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Single voids (evening)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Paired voids (afternoon + overnight for sodium; morning + evening for potassium)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Triple voids (morning + evening + overnight for sodium; morning + afternoon + evening for potassium)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Sample size increase
Number of subjects: 441
Study: 38403186

Group type: EXPERIMENTAL
Intervention: Bilateral transcutaneous noninvasive electromagnetic phrenic nerve stimulation (NEPNS) for 15 minutes, twice daily (bid).
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Bilateral transcutaneous noninvasive electromagnetic phrenic nerve stimulation (NEPNS) without pressure support.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Bilateral transcutaneous noninvasive electromagnetic phrenic nerve stimulation (NEPNS) with additional pressure support.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Bilateral transcutaneous noninvasive electromagnetic phrenic nerve stimulation (NEPNS).
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 11
Study: 38403793

Group type: EXPERIMENTAL
Intervention: Cotadutide (200-μg dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cotadutide
Number of subjects: 0
Study: 38403865

Group type: EXPERIMENTAL
Intervention: AZD7442 (600 mg intramuscular, 300 mg tixagevimab/300 mg cilgavimab)
Number of subjects: 910

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 910
Study: 38403887

Group type: EXPERIMENTAL
Intervention: Multi-component intervention including initiation of antiretroviral therapy (ART) during admission, strengths-based case management, and naltrexone
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Multi-component intervention
Number of subjects: 225
Study: 38403900

Group type: EXPERIMENTAL
Intervention: Questionnaire-based diagnostic model for malignant gastric lesions
Number of subjects: 17360

Group type: EXPERIMENTAL
Intervention: External validation of the questionnaire-based diagnostic model
Number of subjects: 17360
Study: 38403984

Group type: EXPERIMENTAL
Intervention: Shock Index (SI)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Modified Shock Index (MSI)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Diastolic Shock Index (DSI)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Shock Indices (SI, MSI, DSI)
Number of subjects: 151
Study: 38404145

Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 2086

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 2086
Study: 38404479

Group type: EXPERIMENTAL
Intervention: Lung ultrasound score
Number of subjects: 35

Group type: COMPARATOR
Intervention: Right hemidiaphragmatic excursion
Number of subjects: 35
Study: 38404532

Group type: EXPERIMENTAL
Intervention: Educational intervention on oral health
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 172
Study: 38404649

Group type: EXPERIMENTAL
Intervention: TEENS+ family-based lifestyle intervention
Number of subjects: 60
Study: 38404673

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention for chronic pain
Number of subjects: 811
Study: 38404679

Group type: EXPERIMENTAL
Intervention: Lifetime diagnoses of anxiety disorders
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Having a regular gynecologist
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Lifetime diagnoses of bipolar disorder
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Past 6-month sexual IPV histories
Number of subjects: 132
Study: 38404989

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 4714

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 4714
Study: 38405151

Group type: EXPERIMENTAL
Intervention: Hydrocortisone or modified-release hydrocortisone
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Fludrocortisone (lower doses)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Stress dosing
Number of subjects: 168

Group type: COMPARATOR
Intervention: General USA population
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 168
Study: 38405158

Group type: EXPERIMENTAL
Intervention: Live multistrain probiotic and absorbent smectite co-supplementation
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 46
Study: 38405755

Group type: EXPERIMENTAL
Intervention: BAI+SFAS
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: RT+SFAS
Number of subjects: 525

Group type: COMPARATOR
Intervention: Education Control
Number of subjects: 525
Study: 38405781

Group type: EXPERIMENTAL
Intervention: Conditional Cash Transfers (CCTs) continued for one more year
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conditional Cash Transfers (CCTs) discontinued
Number of subjects: 38
Study: 38406514

Group type: EXPERIMENTAL
Intervention: Momelotinib
Number of subjects: 304

Group type: COMPARATOR
Intervention: Ruxolitinib
Number of subjects: 304
Study: 38406813

Group type: EXPERIMENTAL
Intervention: THP regimen (docetaxel 75 mg/m2, trastuzumab biosimilar TQB211 8 mg/kg first cycle, 6 mg/kg maintenance, pertuzumab biosimilar TQB2440 or pertuzumab 840 mg first cycle, 420 mg maintenance)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: THP regimen
Number of subjects: 28
Study: 38406848

Group type: EXPERIMENTAL
Intervention: Postprocedural anticoagulation (PPA)
Number of subjects: 2989

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2989